ERBB2 and cancer: Evaluation of cell surface binding to HER2-expressing cancer cells by flow cytometry showed that zanidatamab had 1.3 to 1.6-fold higher maximum binding capacity (saturation) compared to the monospecific Abs trastuzumab or pertuzumab.